CL2015001643A1 - Formas cristalinas de 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-{4-[(4-metilpiperazin-1-il)metil]-3-(trifluorometil)fenil}benzamida y su sal monoclorhidrato; composicion farmaceutica que las comprende; proceso para preparar la forma cristalina a; y metodo para tratar leucemias seleccionadas de la cml o la ph+ aal. - Google Patents

Formas cristalinas de 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-{4-[(4-metilpiperazin-1-il)metil]-3-(trifluorometil)fenil}benzamida y su sal monoclorhidrato; composicion farmaceutica que las comprende; proceso para preparar la forma cristalina a; y metodo para tratar leucemias seleccionadas de la cml o la ph+ aal.

Info

Publication number
CL2015001643A1
CL2015001643A1 CL2015001643A CL2015001643A CL2015001643A1 CL 2015001643 A1 CL2015001643 A1 CL 2015001643A1 CL 2015001643 A CL2015001643 A CL 2015001643A CL 2015001643 A CL2015001643 A CL 2015001643A CL 2015001643 A1 CL2015001643 A1 CL 2015001643A1
Authority
CL
Chile
Prior art keywords
methyl
iletinyl
aal
pyridazin
methylpiperazin
Prior art date
Application number
CL2015001643A
Other languages
English (en)
Spanish (es)
Inventor
Christopher K Murray
Leonard W Rozamus
John J Chaber
Pradeep Sharma
Original Assignee
Ariad Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50929140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015001643(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ariad Pharma Inc filed Critical Ariad Pharma Inc
Publication of CL2015001643A1 publication Critical patent/CL2015001643A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2015001643A 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-{4-[(4-metilpiperazin-1-il)metil]-3-(trifluorometil)fenil}benzamida y su sal monoclorhidrato; composicion farmaceutica que las comprende; proceso para preparar la forma cristalina a; y metodo para tratar leucemias seleccionadas de la cml o la ph+ aal. CL2015001643A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261736543P 2012-12-12 2012-12-12
US201261737007P 2012-12-13 2012-12-13
US201361788208P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CL2015001643A1 true CL2015001643A1 (es) 2015-10-02

Family

ID=50929140

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001643A CL2015001643A1 (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-{4-[(4-metilpiperazin-1-il)metil]-3-(trifluorometil)fenil}benzamida y su sal monoclorhidrato; composicion farmaceutica que las comprende; proceso para preparar la forma cristalina a; y metodo para tratar leucemias seleccionadas de la cml o la ph+ aal.

Country Status (9)

Country Link
US (9) US9493470B2 (cg-RX-API-DMAC7.html)
JP (4) JP6447508B2 (cg-RX-API-DMAC7.html)
CN (2) CN105188701A (cg-RX-API-DMAC7.html)
CA (3) CA3167093A1 (cg-RX-API-DMAC7.html)
CL (1) CL2015001643A1 (cg-RX-API-DMAC7.html)
HK (1) HK1218878A1 (cg-RX-API-DMAC7.html)
MX (11) MX391445B (cg-RX-API-DMAC7.html)
NZ (1) NZ709648A (cg-RX-API-DMAC7.html)
WO (2) WO2014093583A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2495016T3 (da) 2005-12-23 2019-12-16 Ariad Pharma Inc Bicykliske heteroarylforbindelser
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
CA3167093A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
AU2014286047B2 (en) 2013-07-04 2018-02-08 Sandoz Ag Crystalline forms of ponatinib hydrochloride
CN104496940B (zh) * 2014-01-06 2017-03-15 广东东阳光药业有限公司 一种制备bcr‑abl抑制剂中间体的方法
CA3047107A1 (en) * 2016-12-15 2018-06-21 Ariad Pharmaceuticals, Inc. Benzimidazole compounds as c-kit inhibitors
US10221184B2 (en) 2017-01-20 2019-03-05 Apicore Us Llc Polymorphs of ponatinib hydrochloride
WO2018232501A1 (en) * 2017-06-20 2018-12-27 Apotex Inc. Crystalline forms of ponatinib hydrochloride
KR20250010134A (ko) * 2018-04-02 2025-01-20 스텔스 바이오테라퓨틱스 인코포레이티드 엘라미프레티드의 합성에 유용한 결정질 디펩티드
WO2019246479A1 (en) * 2018-06-22 2019-12-26 Johnson Matthey Public Limited Company Form of ponatinib
CA3118330A1 (en) 2018-11-01 2020-05-07 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2020223235A1 (en) 2019-04-29 2020-11-05 Incyte Corporation Mini-tablet dosage forms of ponatinib
CN111004240B (zh) * 2019-12-13 2020-12-01 山东铂源药业有限公司 一种泊那替尼中间体3-乙炔基咪唑并[1,2-b]哒嗪的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5099067A (en) 1988-08-05 1992-03-24 Northwestern University Use of ammonium formate as a hydrogen transfer reagent for reduction of chiral nitro compounds with retention of configuration
EP1230231B1 (en) 1999-11-08 2005-06-22 Schering Corporation Process for preparing n-(4-hydroxyphenyl)-n'-(4'-aminophenyl)-piperazine
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
DE10021246A1 (de) 2000-04-25 2001-10-31 Schering Ag Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
AR041992A1 (es) 2002-11-06 2005-06-08 Smithkline Beecham Corp Compuesto de piridinil benzoheterociclico, composicion farmaceutica que lo comprende y su uso para prepararla
GB0230089D0 (en) 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
WO2005051366A2 (en) 2003-11-28 2005-06-09 Novartis Ag Diaryl urea derivatives in the treatment of protein kinase dependent diseases
EP1694691A1 (en) 2003-12-05 2006-08-30 Biovitrum Ab Improved synthesis of 2-substituted adenosines
WO2005060969A1 (en) 2003-12-24 2005-07-07 Astrazeneca Ab Pyrimidines with tie2 (tek) activity
ES2317079T3 (es) 2003-12-24 2009-04-16 Astrazeneca Ab Pirimidinas con actividad tie2 (tek).
EA011930B1 (ru) 2004-04-07 2009-06-30 Лаборатуар Сероно Са Карбоновые кислоты
JP2008506702A (ja) 2004-07-14 2008-03-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するための方法
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
JP2008534565A (ja) 2005-03-31 2008-08-28 アストラゼネカ アクチボラグ Ｔｉｅ２阻害活性のあるアミノピリミジン誘導体
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
JP5321061B2 (ja) 2005-08-11 2013-10-23 アリアド・ファーマシューティカルズ・インコーポレイテッド 不飽和複素環誘導体
DK2495016T3 (da) 2005-12-23 2019-12-16 Ariad Pharma Inc Bicykliske heteroarylforbindelser
SI1973545T1 (sl) * 2005-12-23 2013-04-30 Ariad Pharmaceuticals, Inc. Spojine bicikličnega heteroarila
MX2008014290A (es) 2006-05-08 2008-11-26 Ariad Pharma Inc Compuestos heteroarilicos monociclicos.
BRPI0710328A2 (pt) 2006-05-08 2011-08-09 Ariad Pharma Inc composto da fórmula i, um tautomer da mesma, ou um sal farmaceuticamente aceitável, hidrato ou outro solvato do mesmo e método para o tratamento de cáncer em um mamìfero necessitado do mesmo e composição
EP2107054A1 (en) 2008-04-01 2009-10-07 Università Degli Studi Di Milano - Bicocca Antiproliferative compounds and therapeutic uses thereof
US20100273772A1 (en) * 2009-04-23 2010-10-28 Wyeth Llc Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5)
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
EA201290255A1 (ru) * 2009-10-30 2013-04-30 Ариад Фармасьютикалз, Инк. Способы и композиции для лечения рака
EP2694064A1 (en) * 2011-04-07 2014-02-12 Ariad Pharmaceuticals, Incorporated Methods and compositions for treating neurodegenerative diseases
KR20140022062A (ko) 2011-04-07 2014-02-21 어리어드 파마슈티칼스, 인코포레이티드 파킨슨병을 치료하기 위한 방법 및 조성물
US20150105377A1 (en) 2012-04-25 2015-04-16 Ariad Pharmaceuticals, Inc. Methods and Compositions for RAF Kinase Mediated Diseases
CA3167093A1 (en) * 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Also Published As

Publication number Publication date
MX2015007578A (es) 2016-03-21
US20170190707A1 (en) 2017-07-06
HK1218878A1 (zh) 2017-03-17
CA2815506A1 (en) 2014-06-12
WO2014093583A3 (en) 2014-08-07
WO2014093583A2 (en) 2014-06-19
JP7042175B2 (ja) 2022-03-25
US11192897B2 (en) 2021-12-07
MX2021002256A (es) 2021-05-27
JP2018168191A (ja) 2018-11-01
MX2021002264A (es) 2021-05-27
JP2016503010A (ja) 2016-02-01
JP7352841B2 (ja) 2023-09-29
US9493470B2 (en) 2016-11-15
MX2021002253A (es) 2021-05-27
US20210277012A1 (en) 2021-09-09
US20190169196A1 (en) 2019-06-06
MX2021002257A (es) 2021-05-27
CN105188701A (zh) 2015-12-23
US11192896B2 (en) 2021-12-07
US20150315194A1 (en) 2015-11-05
JP2023179498A (ja) 2023-12-19
US20210340149A1 (en) 2021-11-04
JP6447508B2 (ja) 2019-01-09
US11279705B2 (en) 2022-03-22
US10125136B2 (en) 2018-11-13
CA2815506C (en) 2018-12-11
NZ709648A (en) 2020-05-29
MX2021002261A (es) 2021-05-27
US10662197B2 (en) 2020-05-26
WO2014093579A2 (en) 2014-06-19
JP2022037122A (ja) 2022-03-08
US11384086B2 (en) 2022-07-12
CA3022250A1 (en) 2014-06-12
WO2014093579A3 (en) 2014-07-10
MX391445B (es) 2025-03-21
MX2021002254A (es) 2021-05-27
US20210024527A1 (en) 2021-01-28
US11192895B2 (en) 2021-12-07
MX2021002258A (es) 2021-05-27
CN115043843A (zh) 2022-09-13
US20210277011A1 (en) 2021-09-09
US20210277010A1 (en) 2021-09-09
MX2021002255A (es) 2021-05-27
MX2021002259A (es) 2021-05-27
MX359147B (es) 2018-09-17
CA3167093A1 (en) 2014-06-12
US20240083902A1 (en) 2024-03-14

Similar Documents

Publication Publication Date Title
CL2015001643A1 (es) Formas cristalinas de 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-{4-[(4-metilpiperazin-1-il)metil]-3-(trifluorometil)fenil}benzamida y su sal monoclorhidrato; composicion farmaceutica que las comprende; proceso para preparar la forma cristalina a; y metodo para tratar leucemias seleccionadas de la cml o la ph+ aal.
BR112016011065A8 (pt) composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia
DK3699181T3 (da) Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat
IL262304A (en) Methods for providing single-stranded rna
BR112013018953A2 (pt) composição efervescente na forma sólida para uso em aplicações vaginais para o tratamento de infecções vaginais.
IL268850A (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
LT3458456T (lt) (s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamido gavimas
CL2013001891A1 (es) Compuestos heterociclicos fusionados; composicion farmaceutica y uso en el tratamiento de la degeneracion macular asociada con la edad.
CR20160036A (es) Inhibidores cristalinos de bromodominios
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
LT3954690T (lt) (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a] pirazin-1-il)-n-(piridin-2-il)benzamido kompozicijų kietosios formos
IL250239A0 (en) Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient
HUE044960T2 (hu) Légúti szincíciális vírus okozta fertõzések kezelésében hasznos pirrolo-[1,2,F][1,2,4]triazinok
CO6940374A2 (es) Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas
SI3805233T1 (sl) (r)in (s) enantiomera n-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo(4,5-b)piridin-6-il) -2-(2-metilpiridin-4-il)oksazol-karboksamid kot inhibitorji irak4 za zdravljenje raka
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
BR112015002524A2 (pt) derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças.
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
CL2014002348A1 (es) Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado.
IL257371A (en) Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient
EA201591804A1 (ru) Производные 2-((4-амино-3-(3-фтор-5-гидроксифенил)-1h-пиразоло[3,4-d]пиримидин-1-ил)метил)-3-(2-(трифторметил)бензил)хиназолин-4(3h)-она и их применение в качестве ингибиторов фосфоинозитид-3-киназы
HUE046671T2 (hu) Glutárimid származékokat tartalmazó gyógyászati készítmény, valamint ennek alkalmazása eozinofil betegségek kezelésében
IL239940B (en) History of 2-[3-(diazolyl)phenyl]-3,1-thiazole-5-carboxylic acid and intermediates obtained in the process for their preparation
CL2015002488A1 (es) Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen